These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36822269)

  • 1. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
    Schmitz JM; Stotts AL; Yoon JH; Northrup TF; Villarreal YR; Yammine L; Weaver MF; Carmody T; Shoptaw S; Trivedi MH
    J Subst Use Addict Treat; 2023 Aug; 151():208987. PubMed ID: 36822269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.
    Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ
    Addiction; 2024 Jun; ():. PubMed ID: 38856086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.
    Mooney ME; Schmitz JM; Allen S; Grabowski J; Pentel P; Oliver A; Hatsukami DK
    Clin Pharmacol Ther; 2016 Oct; 100(4):344-52. PubMed ID: 27213949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
    Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
    J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion and Naltrexone in Methamphetamine Use Disorder.
    Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
    N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder.
    Wang AL; Shi Z; Elman I; Langleben DD
    Am J Drug Alcohol Abuse; 2020 Jul; 46(4):472-477. PubMed ID: 32379516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
    Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.
    Kidd JD; Smiley SL; Coffin PO; Carmody TJ; Levin FR; Nunes EV; Shoptaw SJ; Trivedi MH
    Drug Alcohol Depend; 2023 Sep; 250():110899. PubMed ID: 37478502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
    Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
    Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.
    Robles GI; Singh-Franco D; Ghin HL
    Clin Ther; 2008 May; 30(5):800-12. PubMed ID: 18555928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
    Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
    Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.
    Levander XA; Carmody T; Cook RR; Potter JS; Trivedi MH; Korthuis PT; Shoptaw S
    Addiction; 2023 Jul; 118(7):1320-1328. PubMed ID: 36864016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
    Toll BA; Leary V; Wu R; Salovey P; Meandzija B; O'Malley SS
    Addict Behav; 2008 Jan; 33(1):173-9. PubMed ID: 17587504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.